New trial tests which chemo combo best shrinks tough breast tumors

NCT ID NCT04138719

Recruiting now Disease control Sponsor: Hebei Medical University Fourth Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial compares two chemotherapy combinations given before surgery for triple-negative breast cancer. About 520 women will receive either nab-paclitaxel plus carboplatin or nab-paclitaxel plus epirubicin. The goal is to see which combo better eliminates cancer cells in the breast and lymph nodes at the time of surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Nab-paclitaxel plus carboplatin or nab-paclitaxel plus epirubicin
What this could lead to: If it works, this could identify a more effective chemotherapy combination to shrink triple-negative breast tumors before surgery, potentially improving outcomes.
What could go wrong: This is a phase 2 trial, so results are preliminary. The study is still recruiting, and it's unclear if one combo will prove clearly better or safer than the other.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER NAB-PACLITAXEL TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

The Fourth Hospital of Hebei Medical University
RECRUITING

Shijiazhuang, Hebei, 050011, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.